SK382001A3 - Pharmaceutical uses of nab1 and nab2 - Google Patents

Pharmaceutical uses of nab1 and nab2 Download PDF

Info

Publication number
SK382001A3
SK382001A3 SK38-2001A SK382001A SK382001A3 SK 382001 A3 SK382001 A3 SK 382001A3 SK 382001 A SK382001 A SK 382001A SK 382001 A3 SK382001 A3 SK 382001A3
Authority
SK
Slovakia
Prior art keywords
nab2
nab1
polypeptide
nucleic acid
acid molecule
Prior art date
Application number
SK38-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Martin Braddock
Callum Jeffrey Campbell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SK382001A3 publication Critical patent/SK382001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK38-2001A 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2 SK382001A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Publications (1)

Publication Number Publication Date
SK382001A3 true SK382001A3 (en) 2001-09-11

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
SK38-2001A SK382001A3 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Country Status (22)

Country Link
EP (1) EP1097200A1 (no)
JP (1) JP2002520020A (no)
KR (1) KR20010071832A (no)
CN (1) CN1317045A (no)
AP (1) AP2001002038A0 (no)
AU (1) AU763713B2 (no)
BR (1) BR9912018A (no)
CA (1) CA2336805A1 (no)
EA (1) EA200100028A1 (no)
EE (1) EE200100020A (no)
HR (1) HRP20010025A2 (no)
HU (1) HUP0102835A3 (no)
ID (1) ID27742A (no)
IL (1) IL140533A0 (no)
IS (1) IS5788A (no)
NO (1) NO20010166L (no)
NZ (1) NZ509174A (no)
PL (1) PL345507A1 (no)
SK (1) SK382001A3 (no)
TR (1) TR200100622T2 (no)
WO (1) WO2000003014A1 (no)
YU (1) YU1901A (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
IL140533A0 (en) 2002-02-10
EP1097200A1 (en) 2001-05-09
KR20010071832A (ko) 2001-07-31
PL345507A1 (en) 2001-12-17
CA2336805A1 (en) 2000-01-20
NZ509174A (en) 2003-08-29
YU1901A (sh) 2005-06-10
AU763713B2 (en) 2003-07-31
TR200100622T2 (tr) 2001-10-22
NO20010166D0 (no) 2001-01-10
EE200100020A (et) 2002-06-17
EA200100028A1 (ru) 2001-08-27
CN1317045A (zh) 2001-10-10
HUP0102835A3 (en) 2003-09-29
NO20010166L (no) 2001-03-06
BR9912018A (pt) 2006-01-31
ID27742A (id) 2001-04-26
JP2002520020A (ja) 2002-07-09
AU4791499A (en) 2000-02-01
HRP20010025A2 (en) 2001-12-31
WO2000003014A1 (en) 2000-01-20
IS5788A (is) 2000-12-22
HUP0102835A2 (hu) 2001-11-28
AP2001002038A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
EP0759067B1 (en) Transforming growth factor alpha h1
AU764039B2 (en) Growth factor homolog ZVEGF3
EP1083934B1 (en) EGR-1 for the manufacture of a medicament for treating wounds
US20030103956A1 (en) Use of HIF-1a variants to accelerate wound healing
SK382001A3 (en) Pharmaceutical uses of nab1 and nab2
US7157439B2 (en) HoxD3, HoxA3, and HoxB3 compositions and methods for improved wound healing
CZ2001142A3 (cs) Použití molekuly nukleové kyseliny
ZA200100193B (en) Pharmaceutical uses of NAB1 and NAB2.
US7790155B2 (en) Calbindin-D28K protection against glucocorticoid induced cell death
MXPA01000386A (en) Pharmaceutical uses of nab1 and nab2
WO2002102982A2 (en) Hoxd3 compositions ad methods for improved wound healing
US20120244615A1 (en) Isolated a-type fhf n-terminal domain peptides and methods of use
US7544670B2 (en) HoxD3, HoxA3 and HoxB3 compositions and methods for improved wound healing
ZA200006963B (en) Gene therapy method.
MXPA00011726A (en) Gene therapy method
CZ20004509A3 (cs) Způsob genové terapie